Veraxa Biotech AG
Veraxa Biotech AG
- Market cap
- $579.37K
Your view on VRXAW
Overview
What the company does, where it operates, and who runs it.
About Veraxa Biotech AG
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Christoph Antz
- Headquarters
- Im Neuenheimer Feld 584, Heidelberg, ZH, DE
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Christoph Antz
- Headquarters
- Im Neuenheimer Feld 584, Heidelberg, ZH, DE
Veraxa Biotech AG is a clinical-stage biopharmaceutical company specializing in next-generation antibody-based cancer therapies. [9] The company is advancing a drug discovery and development engine for ADCs and other novel antibody-based therapy concepts.
[14] It was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). [8, 14]
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Veraxa Biotech AG. Starting points for Veraxa Biotech AG: beta 0.60 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Veraxa Biotech AG. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Veraxa Biotech AG. Veraxa Biotech AG has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| AVE.AXAvecho Biotechnology Limited | Healthcare | ASX | — | ||
| AVEFFAvecho Biotechnology Limited | Healthcare | OTC | $13.4M | ||
| AVIRAtea Pharmaceuticals, Inc. | Healthcare | NASDAQ | $320.4M | ||
| AVLNAvalyn Pharma Inc. Common Stock | Healthcare | NASDAQ | $1.2B | ||
| AVTXAvalo Therapeutics, Inc. | Healthcare | NASDAQ | $387.4M | ||
| AVXLAnavex Life Sciences Corp. | Healthcare | NASDAQ | $66.7M | ||
| AXIMAXIM Biotechnologies, Inc. | Healthcare | OTC | $3.7M | ||
| AXSMAxsome Therapeutics, Inc. | Healthcare | NASDAQ | $7.0B | ||
| AZTRAzitra, Inc. | Healthcare | AMEX | $3.5M | ||
| BBIOBridgeBio Pharma, Inc. | Healthcare | NASDAQ | $15.2B | ||
| BBIXFBonus BioGroup Ltd. | Healthcare | OTC | $157.7M | ||
| BBLGBone Biologics Corporation | Healthcare | NASDAQ | $986,216 | ||
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Veraxa Biotech AG executives and directors. Shares of Veraxa Biotech AG have traded between $0.09 and $0.10 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Veraxa Biotech AG. Coverage tracks Veraxa Biotech AG within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Veraxa Biotech AG.